TransMedics Group, Inc. — Director's Dealing 2022

Aug 15, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: TransMedics Group, Inc. (TMDX)
CIK: 0001756262
Period of Report: 2022-08-11

Reporting Person: Hassanein Waleed H (Director, President & CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-08-11	Common Stock	S	12929	$46.74	Disposed	493285	Direct
2022-08-12	Common Stock	S	7000	$48.00	Disposed	486285	Direct

Footnotes

F1: Represents a sale of shares of common stock to generate cash for the payment of taxes, including estimated taxes, due as a result of the vesting or settlement of certain equity-based awards or the exercise of stock options as permitted by the lock-up agreement, dated August 3, 2022, among the Reporting Person, J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC and Cowen and Company, LLC as the representatives of the underwriters named therein.

F2: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $46.39 to $47.26, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.